艾德生物 reported revenue of ¥0.56B for the period ended 2026-06-30, -3.5% year on year. Net income was ¥0.17B, a 29.7% net margin on a 83.4% gross margin. The largest revenue line is 检测试剂 at 81% of the total. Free cash flow for the period was ¥0.08B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.56B | -3.5% |
| Gross profit | ¥0.47B | — |
| Operating income | ¥0.19B | — |
| Net income | ¥0.17B | -12.1% |
| Gross margin | 83.4% | Net margin 29.7% |
| Revenue Q/Q | +14.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 检测试剂 | ¥0.45B | 80.8% |
| 药物临床研究服务 | ¥0.06B | 10.7% |
| 检测服务 | ¥0.04B | 7.6% |
| 其他(补充) | ¥0.00B | 0.8% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.09B | 16.6% |
| R&D | ¥0.09B | 16.3% |
| SG&A | ¥0.16B | 29.0% |
| Tax & other | ¥0.02B | 4.3% |
| Item | Amount |
|---|---|
| Total assets | ¥2.21B |
| Total liabilities | ¥0.32B |
| Shareholders' equity | ¥1.89B |
| Equity / assets | 85.5% |
| Operating cash flow | ¥0.09B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.08B |
| Cash conversion (OCF / net income) | 117% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
智动力 ・ 赛意信息 ・ 创业黑马 ・ 澄天伟业 ・ 双一科技 ・ 联合光电 ・ 中赋科技 ・ 盛弘股份 ・ 蠡湖股份 ・ 兆丰股份 ・ 爱乐达 ・ 电工合金
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies